FAIRWAY WILL RETURN AS SUPER SPONSOR
FOR OUR 2013 SPINODYSSEY
FOOD & BEVERAGE SPONSOR
DR. ELLEN MAHONY
Bottle Sponsor . . . AGAIN!
131 kings highway north • westport 203.221.0102
MEET the RESEARCHERS YOU FUNDED by
Participating in SPINODYSSEY 2012
AARON GOLDMAN, PhD
Aaron Goldman, PhD
Post Doctoral Research Fellow, Harvard Medical School
Division of Biomedical Engineering, Brigham and Women's Hospital
65 Landsdowne St. Cambridge, MA 02139
Breast cancer recurrence is often accompanied by the acquisition of
chemotherapy-resistance. We now know that within breast cancer, some cells are sensitive to chemotherapy while others resist treatment and regrow more aggressively than before. My research elucidates novel cellular processes which allow certain populations of breast cancer cells to tolerate the effects of chemotherapy. Using this knowledge, we engineer nano-scale therapeutics to specifically target chemotherapy tolerant breast cancer cells, prevent relapse and reduce the side-effects associated with treatment.
All the best, Aaron
AWARDS and FRIENDS • SPINODYSSEY 2012
Survivor and SO Committee Co Chair Terry Polley, Chairperson Patty Kondub and
Peg Camp - Chief Operating Officer at American Cancer Society, New England Division
L - R: Back Row: ACS: Woman - Name & Title to come • Michael Mehlner of the ACS Research Dept. • SPINODYSSEY Committee Members: Don Stillman
Barry Ficken • Sharon Simon • Herb Wexler
L - R: Front Row: John Dugdale • Chairperson Patty Kondub • Sharon Benton
THANKS TO YOU THE TOTAL WAS $311,334
RAISED FOR BREAST CANCER RESEARCH in SPINODYSSEY 2012
Online donation pages always stay open,
so more contributions are coming in every day!
SPINODYSSEY 2011 AWARDED $649,000 to
Douglas Hurst, Ph.D. University of Alabama at Birmingham for his four year research titled:
"Composition of SIN3 protein complexes in breast cancer metastasis"
"Words cannot begin to express my gratitude toward SPINODYSSEY 2011, and ACS for
funding my project. The pressure is now on us to produce meaningful results".
Metastasis is the major reason for morbidity and mortality of breast cancer patients. Every sequential step in the process of metastasis requires specific sets of genes to be turned on or off. These gene sets are regulated in part through large protein complexes that re-organize the structure of DNA and how it is interacting with associated proteins (chromatin). The current focus of our lab is to characterize the composition and enzyme activity of these chromatin modifying complexes that regulate the process of breast cancer metastasis. These studies will provide the necessary groundwork for the identification of novel targets to enable treatment of metastatic breast cancer.